J INTS BIO South Korea California

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA

View original content:https://www.prnewswire.co.uk/news-releases/j-ints-bio-phase-12-study-of-jin-a02-a-novel-oral-4th-generation-egfr-tki-accepted-for-presentation-at-the-upcoming-american-association-for-cancer-research-2024-meeting-in-usa-aacr-2024-302070829.html